Wockhardt News

The credit facilities committee of the board at its meeting held on May 21 has approved the raising of funds up to Rs 150 crore. The Mumbai-based drug maker, however, did not share details as to where it plans to utilise the capital.

Drug firm Wockhardt is seeking shareholders' nod to raise up to Rs 1,000 crore via issue of securities.

Delhi High Court today stayed the the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.

In Mumbai trading so far this year, Lupin Ltd has climbed 32 percent, Dr. Reddy`s 31 percent, Glenmark Pharmaceuticals 42 percent and Wockhardt 29 percent.

Continued strength in the dollar when the Federal Reserve raises interest rates will also boost their income. More than 40 percent of over-the-counter and generic prescription drugs sold in the United States come from India.

Sun Pharma and Wockhardt have separately initiated voluntary recall of a number of drugs from the US market due to different reasons.

Wockhardt is recalling over 50 lakh bottles of various drugs, used for treating ailments like high blood pressure and ulcer, in the US market due to deviations in current good manufacturing practice norms laid down by the American health regulator.

Drug firm Wockhardt, which has been under the USFDA scanner, Thursday said that United States health regulator has completed inspection of its Nalagarh facility in Himachal Pradesh.

As per the information available on the US Food and Drug Administration's (USFDA) website, Mumbai-based Wockhardt is recalling the drugs for current good manufacturing practice (CGMP) deviations.

Shares of drug firm Wockhardt rose by nearly 3 percent on Monday as the company received approval from the US health regulator to market its Oxycodone HCl liquid, used for treating chronic pain, in the American market.

According to information on the US Food and Drug Administration (USFDA) website, 166 bottles of Captopril tablets of 50 mg strength are being recalled in the US.

The company has now increased its R&D spend and filed more ANDAs in the US and Britain for approvals.

Drug firm Wockhardt, which has been under the USFDA's scanner, Wednesday said that the American health regulator has completed the inspection of its Waluj facility in Maharashtra.

Recall has been initiated as the tablets failed to meet tablet/capsule specifications given by the USFDA.

After falling 11.2 percent to Rs 1,181 in intra-day trade on the BSE, shares of the company finally ended at Rs 1,243.35, down 6.52 percent.

Pharmaceuticals major Wockhardt is recalling 13 drugs in the US, manufactured at its two units at Chikalthana and Waluj in Maharashtra, which were under import restrictions from the USFDA.

"The recent inspection at the Aurangabad L1-Chikalthana site was a follow-up inspection by the US FDA as an outcome of completion of good manufacturing practise (GMP) remediation submitted by Wockhardt in October 2014.

Shares in Wockhardt Ltd fell as much as 5.3 percent on Thursday after the drugmaker said the U.S. Food and Drug Administration had raised fresh concerns about a plant already banned from exporting to the United States over quality issues.

This is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued here.

Drug maker Wockhardt on Sunday said that two of its anti-infective drugs have received Qualified Infectious Disease Product (QIDP) status from the US health regulator.